An Investigation of Frailty Markers and Outcomes in Patients Requiring Emergency Laparotomy
NCT ID: NCT05416047
Last Updated: 2023-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2022-05-30
2024-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to establish blood tests (biomarkers) associated with frailty, explore the ability of frailty markers measured before EmLAP to predict death after EmLAP, define changes in frailty in EmLAP patients and analyse the influence of frailty on quality of life post EmLAP.
Over 2 years, 150 patients age ≥40 undergoing EmLAP in a hospital will be recruited and followed up for 90 days looking at different frailty markers. These include (a)blood tests (biomarkers) analysed in a special laboratory machine called mass spectrometer to identify chemical markers linked to frailty status (b)CT scan looking at muscle bulk (sarcopenia) (c)Rockwood Clinical Frailty Score, a scoring system assessing how much a patient can do (1 is fit; 9 is extremely frail).
The investigators hope that these results will improve our understanding of frailty and lead to further research to improve outcomes for EmLAP patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Analysis of Sarcopenia in Older Patients Undergoing Laparotomy
NCT04493710
Frailty and Postoperative Outcomes After Gastric Cancer Surgery
NCT03568110
The Patient in Laparoscopic Colon Surgery:Impact of Comorbidities,Frailty,Malnutrition and Sarcopenia on Short-term Mortality
NCT04729738
Limb Remote Ischemic Preconditioning for Heart and Intestinal Protection During Laparoscopic Colorectal Surgery
NCT01832337
Colectomy for Cancer in the Elderly by Laparoscopy or Laparotomy
NCT03033719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Frailty is a clinical syndrome of increased vulnerability that results from ageing associated multi-system physiological decline resulting in reduction of the individual's ability to cope with physiological stress such as surgery. Frailty can be identified using different assessments but due to practicality in emergency setting, the Rockwood Clinical Frailty Score (CFS) is increasingly used and has been incorporated in NELA. Frailty is not unique to the older EmLAP population, it is also present in 16% of adults aged 40 to 65 years. If frailty pre-EmLAP is prevalent, then it must be remembered that surgery can induce frailty in non-frail patients and worsening frailty in those that were already frail (surgical frailty).
Overall, there is lack of understanding in the biochemical aetiology of frailty. Early detection of subclinical changes and changes at the molecular level are key to enhancing our understanding of the biology of frailty and ultimately improving patients outcomes. This study aims to establish blood based biomarkers that could identify frailty objectively in EmLAP patients. The secondary aims are to compare preoperative frailty markers in their ability to predict 30 and 90-day mortality post-EmLAP, define perioperative changes in frailty in patients undergoing EmLAP and analyse the influence of perioperative frailty on morbidity and quality of life post- EmLAP.
Methods A prospective single centred observational study will be conducted over on 150 patients ≥40 years of age that undergo EmLAP over 2years. Patients will be included according to the established NELA criteria. The variables collected include demographics, co-morbidities using, polypharmacy, lifestyle, place of residence, indication and type of surgery (as per NELA criteria) and prognostic NELA score.
The frailty markers will be collected preoperatively and post- operatively day 1 and 7:
1. Blood sample for mass spectrometry analysis (additional blood tube on top of routine bloods)
2. Preoperative CT abdomen pelvis
3. Malnutrition Universal Screening Tool (MUST) score (recorded on admission)
4. Abbreviated Mental Test (AMT) score (recorded on admission)
5. Routine serum biochemistry and haematology: Hb, White cells, C- Reactive protein, Albumin
6. Rockwood Clinical Frailty Score (CFS). Score 1 -9 with frail as ≥4.
Other follow-up data collection:
1. Day 30 and 90 mortality assessed from medical records
2. Place of residence post discharge following EmLAP
3. Day 30 and 90 blood samples for mass spectrometry analysis
4. 30 day morbidity (according Clavien Dindo classification)
5. Total hospital stay including critical care stay
6. Day 30 and 90 quality of life post EmLAP using EQ5D-5L.
The frailty markers will be compared between groups of frail and non-frail patients using statistical methods such as regression model and adjust for appropriate confounding variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Frail and no frail
Frailty will be assessed using Rockwood Clinical Frailty Score
No interventions assigned to this group
Sarcopenia and no sarcopenia
Sarcopenia will be assessed using psoas muscle mass
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Open, laparoscopic, or laparoscopically-assisted procedures
* Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction
* Washout/evacuation of intra-peritoneal abscess (unless due to appendicitis or cholecystitis - excluded, see below)
* Washout/evacuation of intra-peritoneal haematoma
* Bowel resection/repair due to incarcerated incisional, umbilical, inguinal and femoral hernias (but not hernia repair without bowel resection/repair). E.g. Large incisional hernia repair with bowel resection Bowel resection/repair due to obstructing/ incarcerated incisional hernias provided the presentation and findings were acute. This will include large incisional hernia repair with division of adhesions.
* Laparotomy/laparoscopy with inoperable pathology (e.g. peritoneal/hepatic metastases) where the intention was to perform a definitive procedure. This does not include purely diagnostic procedures.
* Laparoscopic/Open Adhesiolysis
* Return to theatre for repair of substantial dehiscence of major abdominal wound (i.e. "burst abdomen")
Exclusion Criteria
* CT scan or postoperative finding of inoperable disseminated peritoneal disease
* Open and close laparotomy (postoperative palliation, non-survivable global ischemia where there are \<90cm from duodenojejunal junction to stoma)
* Complication from colonic stenting requiring laparotomy
* Elective laparotomy / laparoscopy
* Diagnostic laparotomy/laparoscopy where no subsequent procedure is performed (NB, if no procedure is performed because of inoperable pathology, then include)
* Appendicectomy +/- drainage of localised collection unless the procedure is incidental to a non-elective procedure on the GI tract
* Cholecystectomy +/- drainage of localised collection unless the procedure is incidental to a non-elective procedure on the GI tract (All surgery involving the appendix or gallbladder, including any surgery relating to complications such as abscess or bile leak is excluded. The only exception to this is if carried out as an incidental procedure to a more major procedure. There might be extreme cases of peritoneal contamination, but total exclusion avoids subjective judgement calls about severity of contamination.)
* Non-elective hernia repair without bowel resection or division of adhesions
* Minor abdominal wound dehiscence unless this causes bowel complications requiring resection.
* Non-elective formation of a colostomy or ileostomy as either a trephine or a laparoscopic procedure (NB: if a midline laparotomy is performed, with the primary procedure being formation of a stoma then this should be included)
* Vascular surgery, including abdominal aortic aneurysm repair
* Caesarean section or obstetric laparotomies
* Gynaecological laparotomy
* Ruptured ectopic pregnancy, or pelvic abscesses due to pelvic inflammatory disease
* Laparotomy/laparoscopy for pathology caused by blunt or penetrating trauma
* All surgery relating to organ transplantation (including returns to theatre for any reason following transplant surgery)
* Surgery relating to sclerosing peritonitis
* Surgery for removal of dialysis catheters
* Laparotomy/laparoscopy for oesophageal pathology
* Laparotomy/laparoscopy for pathology of the spleen, renal tract, kidneys, liver, gall bladder and biliary tree, pancreas or urinary tract
* Returns to theatre for complications (eg bowel injury, haematoma, collection) following non-GI surgery are now excluded. i.e returns to theatre following renal, urological, gynaecological, vascular, hepatic, pancreatic, splenic surgery are excluded
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Strathclyde
OTHER
NHS Greater Glasgow and Clyde
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Alexandra Hospital
Paisley, Renfrewshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ng HJ, Rattray NJW, Quasim T, Moug SJ. Changes in frailty status and discharge destination post emergency laparotomy. World J Emerg Surg. 2025 Apr 25;20(1):37. doi: 10.1186/s13017-025-00612-8.
Ng HJ, Quasim T, Rattray NJW, Moug S. Investigation of frailty markers including a novel biomarker panel in emergency laparotomy: protocol of a prospective cohort study. BMC Surg. 2023 Jul 5;23(1):190. doi: 10.1186/s12893-023-02093-5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN20SG508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.